Table 2.
Adjusted mean difference from baseline (mean) and standard error (SE) of total cholesterol (TC), LDL-cholesterol (LDL), total cholesterol/HDL-cholesterol ratio (TC/HDL) and triglycerides (TG) one year after the switch
| Switch | TC T2 - TC T0 (mg/dl) |
LDL T2 - LDL T0 (mg/dl) |
HDL T2 - HDL T0 (mg/dl) |
TC/HDL T2 - TC/HDL T0 (mg/dl) |
TG T2 - TG T0 (mg/dl) |
FRS T2 - FRS T0 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| From | To | mean (±SE) | p* | mean (±SE) | p* | mean (±SE) | p* | mean (±SE) | p* | mean (±SE) | p* | mean (±SE) | p§ |
| 2 NRTI + EFV | DTG | −15.0 ± 6.5 | .0210 | − 10.9 ± 6.2 | .0771 | −1.4 ± 1.8 | .4222 | − 0.21 ± 0.21 | .3242 | − 19.6 ± 15.2 | .1992 | 0.67 ± 0.71 | 0.35 |
| EVG | 1.7 ± 8.6 | .8401 | − 5.9 ± 8.0 | .4623 | 2.8 ± 2.4 | .2350 | − 0.32 ± 0.27 | .2488 | 27.2 ± 20.5 | .1853 | 0.74 ± 0.92 | 0.42 | |
| RPV | −31.6 ± 5.3 | <.0001 | −21.0 ± 5.0 | <.0001 | − 2.9 ± 1.4 | .0421 | − 0.52 ± 0.17 | .0021 | −31.5 ± 12.4 | .0116 | 0.03 ± 0.38 | 0.93 | |
| 2 NRTI + PI/r | DTG | −16.8 ± 5.9 | .0049 | −8.8 ± 5.7 | .1247 | 2.4 ± 1.6 | .1335 | − 0.60 ± 0.19 | .0015 | −26.1 ± 14.0 | .0628 | − 0.54 ± 0.60 | 0.36 |
| EVG | −16.6 ± 5.8 | .0044 | − 12.0 ± 5.6 | .0312 | 3.0 ± 1.6 | .0604 | − 0.63 ± 0.18 | .0007 | −23.0 ± 16.6 | .0926 | −0.87 ± 0.52 | 0.10 | |
| RPV | − 20.7 ± 5.2 | <.0001 | −13.6 ± 5.0 | .0064 | 0.00 ± 1.4 | .9995 | − 0.52 ± 0.17 | .0021 | − 28.2 ± 12.2 | .0216 | −0.25 ± 0.48 | 0.60 | |
NRTI nucleoside reverse transcriptase inhibitors; EFV efavirenz, PI/r ritonavir-boosted protease inhibitors, DTG dolutegravir, EVG elvitegravir, RPV rilpivirine, T0 baseline, T2 one year follow up. Significant p values (p < 0.05) are indicated by bold font
*Adjustment for age, sex, baseline value of the analyzed variable, time on antiretroviral therapy, diabetes and use of statin
§ Adjustment for baseline value of FRS and time on antiretroviral therapy